We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

64 hedge funds and large institutions have $21.4M invested in Northwest Biotherapeutics, Inc. Common stock in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

14% less funds holding

Funds holding: 7464 (-10)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

62% less call options, than puts

Call options by funds: $132K | Put options by funds: $347K

65% less capital invested

Capital invested by funds: $61M → $21.4M (-$39.6M)

Holders
64
Holders Change
-10
Holders Change %
-13.51%
% of All Funds
1.71%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
16
Increased
12
Reduced
20
Closed
26
Calls
$132K
Puts
$347K
Net Calls
-$215K
Net Calls Change
+$100K
Name Holding Trade Value Shares
Change
Change in
Stake
AQR Capital Management
76
AQR Capital Management
Connecticut
-$17K -11,464 Closed
Legal & General Group
77
Legal & General Group
United Kingdom
-$14K -9,752 Closed
Teacher Retirement System of Texas
78
Teacher Retirement System of Texas
Texas
-$11K -7,377 Closed
WIC
79
Woodmont Investment Counsel
Tennessee
-$6K -4,198 Closed
Simplex Trading
80
Simplex Trading
Illinois
-$2.99K -2,800 -70%
BlackRock
81
BlackRock
New York
-$3K -1,826 Closed
Zurich Cantonal Bank
82
Zurich Cantonal Bank
Switzerland
-$1.51K -1,416 -83%
WAM
83
Wolverine Asset Management
Illinois
-$516 -483 Closed
AG
84
Advisor Group
Arizona
+$213 +200 New
PCM
85
Prelude Capital Management
New York
+$747 +700 New

NWBO Hedge Fund Activity: Q2 2016 in Review

64 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2016, worth a combined $21.4M — down 65% from $61M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of NWBO and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $491K. The largest seller was Sabby Management, cutting an estimated $2.6M.

  • 64 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2016, down from 74 in Q1 2016.
  • Funds reported $21.4M of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2016, down 65% quarter-over-quarter.
  • 16 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2016 and 26 closed out, a net change of -10 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2016 was Millennium Management, an estimated $491K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2016 was Sabby Management, an estimated $2.6M sold.

Based on aggregated 13F filings for Q2 2016.